Provost Santiago Schnell traveled to Washington, D.C. to meet with administration and agency officials, advocating for the involvement of higher education in setting science and technology policy and for the release of funding for grants awarded by the National Institutes of Health.

President Sian Beilock attended the spring meeting of the Association of American Universities, where she discussed college affordability initiatives and federal funding issues with fellow president and chancellors. She also met with Rep. Chris Pappas (D-NH) to discuss how Dartmouth is working to improve housing in the Upper Valley, and with several think tanks to strategize how to rebuild public trust in higher education. 

Vice Provost for Research Dean Madden attended the Association of American Universities' Senior Research Officers meeting March 2-3. He also met with New Hampshire delegation staff to champion the importance of federally funded research for the Granite State and to urge the continuation of robust funding.

President Sian Beilock helped to organize and participated in an Association of American Universities summit about renewing trust in research universities with the American public. While in Washington, D.C., she met with Sen. Bill Hagerty (R-TN) to discuss strategies to build Congressional support for higher education reform legislation and with administration officials. 

Dartmouth joined an amicus brief in support of Harvard's lawsuit against the Department of Homeland Security alongside 47 other colleges and universities. The lawsuit involves DHS’ purported termination of Harvard’s ability to participate in its Student Exchange Visitor Information System (SEVIS), which would effectively end Harvard’s ability to enroll international students and to host visiting scholars. 

The brief highlights a few examples of the contributions that international students and scholars have made at Dartmouth, including the invention of the BASIC computer programming language; advancements in cybersecurity; the founding of numerous biotechnology companies; and the discovery of new ways to produce antibodies and other human therapeutic proteins.